Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margaret Frame

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Molecular and Cellular Biology|February 2, 2006
AP-1 differentially expressed proteins Krp1 and fibronectin cooperatively enhance Rho-ROCK-independent mesenchymal invasion by altering the function, localization, and activity of nondifferentially expressed proteinsHeather J Spence, Lynn McGarry, Catherine S Chew, et al.
Oncotarget|November 12, 2016
Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cellsLindsay C Spender, G John Ferguson, Sijia Liu, et al.
Nature Communications|May 2, 2022
A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapiesJamie I Scott, Lorena Mendive-Tapia, Doireann Gordon, et al.
Cancer Cell|December 16, 2014
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanomaMaria Romina Girotti, Filipa Lopes, Natasha Preece, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Molecular and Cellular Biology|February 2, 2006
AP-1 differentially expressed proteins Krp1 and fibronectin cooperatively enhance Rho-ROCK-independent mesenchymal invasion by altering the function, localization, and activity of nondifferentially expressed proteinsHeather J Spence, Lynn McGarry, Catherine S Chew, et al.
Oncotarget|November 12, 2016
Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cellsLindsay C Spender, G John Ferguson, Sijia Liu, et al.
Nature Communications|May 2, 2022
A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapiesJamie I Scott, Lorena Mendive-Tapia, Doireann Gordon, et al.
Cancer Cell|December 16, 2014
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanomaMaria Romina Girotti, Filipa Lopes, Natasha Preece, et al.
Pageof 2